R1 RCM Inc

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

R1 RCM Inc (RCM) posts strong Q4 results, eyes Cloudmed growth

R1 RCM Inc (RCM) delivered robust financial performance in Q4 2022, focusing on operational excellence, technology investments, and customer engagement. Challenges include integration efforts and seasonality affecting incentive fees. The company is poised for growth with opportunities in Cloudmed expansion and AI utilization.

R1 RCM Inc (RCM) reports strong Q1 results and growth opportunities

R1 RCM Inc (RCM) delivered strong Q1 results, with a focus on operational improvements, robust Cloudmed growth, and positive financial outlook for 2023.
The company showcased resilience in stable patient self-pay trends, improving payer reimbursement timelines, and strategic capacity for onboarding new NPR, positioning itself for continued success.
Challenges include industry financial pressures, sustaining growth in legacy business, and managing operational costs effectively, requiring strategic adaptation and continuous innovation.
Opportunities lie in pipeline visibility for deals, sequential EBITDA growth, integration of Cloudmed capabilities, and strategic onboarding plans, offering avenues for expansion and profitability.

R1 RCM Inc reports robust Q2 earnings, eyes growth opportunities

R1 RCM Inc's Q2 performance was strong, with a focus on technology and operational enhancements. Challenges include revenue adjustments and workforce implications of automation. Opportunities lie in improved payer dynamics and growth through physician market focus and cross-selling.

R1 RCM Inc reports robust Q3 performance and eyes growth

R1 RCM Inc's Q3 earnings call highlighted strong financial performance, strategic priorities, and challenges in pediatric contracts and integration issues.
The company's focus on revenue optimization, leveraging technology, and partnership with Microsoft positions it well for growth opportunities within the customer base and offshoring initiatives.
While facing challenges in deal timings and debt repayment, R1 RCM Inc's emphasis on operational metrics, customer relationships, and workforce management presents avenues for continued success and industry leadership.

R1 RCM Inc reports robust Q4 earnings, eyes growth opportunities

R1 RCM Inc's Q4 2023 earnings call highlighted strong financial performance, strategic objectives for 2023, and a confident outlook for sustainable growth and shareholder value creation.
The company's emphasis on customer-centricity, AI integration, and operational efficiency underscores its strengths in revenue growth and market positioning.
While facing challenges in credit allowances and customer health, R1 RCM Inc aims to leverage opportunities in reduced costs, synergies from acquisitions, and strategic sales to drive future growth.

R1 RCM reports resilient Q1 performance post-cyberattack, eyes growth

R1 RCM showcased resilience in Q1 2024 despite the Change Healthcare cyberattack, focusing on growth strategies, operational excellence, and technology innovation.
The company faces challenges from the cyberattack impact on KPIs and vendor changes but sees opportunities in the managed care environment and customer engagement.
Overall, R1 RCM remains optimistic about transforming the industry through technology and expertise, with a strong market demand for its solutions.

R1 RCM Inc reports robust Q2 earnings amidst cyberattack challenges

R1 RCM Inc's Q2 2024 earnings call showcased strong financial performance, operational resilience in the face of cyberattacks, and a strategic focus on growth initiatives. The company faces challenges related to pending transactions and cyberattack impacts but sees opportunities in expanding its platform and leveraging technology for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models, patient engagement strategies, or settings of care. The company uses a proven operating model based on the R1 Performance StackSM designed to fit seamlessly into any healthcare organization’s infrastructure and to enhance the patient experience, improve provider economics, and provide revenue predictability. R1 RCM was founded on 2003 and is based in Chicago, Illinois.

R1 RCM Inc. (RCM) delivered earnings and revenue surprises of -200% and 2.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

R1 RCM Inc. (RCM) Reports Q4 Loss, Tops Revenue Estimates

MURRAY, Utah, Feb. 16, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months and year ended December 31, 2022.

R1 RCM Reports Fourth Quarter and Full Year 2022 Results

Top rankings in Ambulatory RCM Services, Robotic Process Automation and Denials Management Services underscore expertise and ability to deliver complete range of flexible healthcare revenue cycle solutions Top rankings in Ambulatory RCM Services, Robotic Process Automation and Denials Management Services underscore expertise and ability to deliver complete range of flexible healthcare revenue cycle solutions

R1 RCM & Cloudmed Ranked #1 by KLAS in Multiple Categories for 2023

MURRAY, Utah, Jan. 26, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months and full year ended December 31, 2022, before market open on Thursday, February 16, 2023.

R1 RCM to Release Fourth Quarter 2022 Results on February 16

Jennifer Williams Appointed Chief Financial Officer; Kyle Hicok Appointed Chief Commercial Officer Jennifer Williams Appointed Chief Financial Officer; Kyle Hicok Appointed Chief Commercial Officer

R1 RCM Announces Leadership Appointments; Reaffirms 2022 Guidance and Announces 2023 Outlook

MURRAY, Utah, Dec. 22, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 41st Annual J.P. Morgan Health Care Conference on Tuesday, January 10, 2023, at 7:30 am PT.

R1 RCM to Present at the 41st Annual J.P. Morgan Health Care Conference

Amgen

Baker Hughes Co

DexCom

Estee Lauder

Okta

Progressive

SVB Financial Group

All the companies that we follow here at 24/7 Wall St. keep a curated list for their institutional and high net worth retail clients of their highest conviction stock picks.

Jefferies Makes Massive 2023 Changes to ‘Strong Buy' Franchise List of Top Stock Picks

It was a strong quarter of growth for RCM, with notable upsides from the previous year. The underlying market is a standout too with favorable economics.

R1 RCM: Reversal Rally Well Supported In The Data

AMC Entertainment

Axsome Therapeutics

Chegg

Chart Industries

Rumble Inc

Twilio

10X Genomics

YETI

The stock market witnessed an upward trend last month, a continuation from October.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in November 2022

Radnor, Pennsylvania--(Newsfile Corp. - December 1, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of R1 RCM Inc. (NASDAQ: RCM) ("R1 RCM").On November 8, 2022, R1 RCM reported its third-quarter operating results and revealed a GAAP net loss of $29.5 million, compared to net income of $17.0 million in the same period last year.

Securities Investigation: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Investors of R1 RCM Inc. (RCM)

RADNOR, Pa.--( BUSINESS WIRE )--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of R1 RCM Inc. (NASDAQ: RCM) (“R1 RCM”).

Securities Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Investors of R1 RCM Inc. (NASDAQ: RCM)

The company's shares are recovering from a big tumble earlier this month.

Why Shares of R1 RCM rose 10% on Tuesday

Los Angeles, California--(Newsfile Corp. - November 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("R1" or "the Company") (NASDAQ: RCM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("R1" or "the Company") (NASDAQ: RCM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 10, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofR1 RCM Inc. ("R1" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 10, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("R1" or "the Company") (NASDAQ: RCM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

San Diego, California--(Newsfile Corp. - November 9, 2022) - Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether R1 RCM Inc. (NASDAQ: RCM), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

R1 RCM Shareholder News: Johnson Fistel Encourages RCM Shareholders with Losses to Contact the Firm Regarding Class Action Investigation

MILWAUKEE , Nov. 9, 2022 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against R1 (Nasdaq: RCM). The investigation results from inaccurate statements R1 may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against R1 RCM Inc.

Shares of R1 RCM Inc. RCM, -51.93% plummeted a record 51.7% toward a 4 1/2-year low in afternoon trading Tuesday, after provider of revenue cycle management services to health care providers missed quarterly profit expectations for the first time post-pandemic, and said a customer facing financial challenges failed to meet a payment deadline. Separately, the company said long-time Chief Executive Joe Flanagan will step down from the role after almost 10 years with the company.

R1 RCM stock suffers record selloff of more than 51% after rare profit miss, physician customer missed payment

Some healthcare market investors are probably feeling ill today, as financial traders are dumping R1 RCM (NASDAQ: RCM ) stock like there's no tomorrow. What are they reacting to?

Why Is R1 RCM Stock Down 40% Today?

R1 RCM Inc. (NASDAQ:RCM ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Atif Rahim - Head, Investor Relations Joe Flanagan - Chief Executive Officer Lee Rivas - President Rachel Wilson - Executive Vice President, Chief Finance Officer and Treasurer Conference Call Participants Charles Rhyee - Cowen Sean Dodge - RBC Capital Markets Scott Schoenhaus - KeyBanc Capital Markets Michael Cherney - Bank of America George Hill - Deutsche Bank Elizabeth Anderson - Evercore ISI Jailendra Singh - Truist Securities Stephanie Davis - SVB Securities Operator Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your conference operator today.

R1 RCM Inc. (RCM) Q3 2022 Earnings Call Transcript

R1 RCM Inc. (RCM) delivered earnings and revenue surprises of -163.64% and 5.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

R1 RCM Inc. (RCM) Reports Q3 Loss, Misses Revenue Estimates

Lee Rivas Appointed Chief Executive Officer, effective January 1, 2023; Joseph Flanagan to Continue Serving on Board

R1 RCM Announces Leadership Succession Plan

MURRAY, Utah, Nov. 08, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2022.

R1 RCM Reports Third Quarter 2022 Results

R1 RCM Inc. (RCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for R1 RCM Inc Stock (RCM)